Plain-English translation of NCT05983237 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Melanoma research guide →Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This clinical trial is testing whether fluzoparib, combined with two other medications (camrelizumab and temozolomide), can be effective for treating advanced melanoma. The study focuses on patients whose melanoma has specific genetic mutations that affect how cancer cells repair their DNA. Researchers believe this combination of treatments may be particularly effective for people with these genetic changes.
About 18–40% of melanoma patients have mutations in genes that control DNA repair, which makes their cancer cells potentially vulnerable to a newer class of drugs called PARP inhibitors. This trial exists to see whether the medication, paired with immune-boosting and chemotherapy drugs, can take advantage of these genetic weaknesses to fight the cancer more effectively.
You likely qualify if…
You likely don't qualify if…
If you join this study, you would receive all three medications as part of your treatment plan. The exact schedule of visits and how long you continue treatment would be determined by your doctor, but you would be monitored regularly with scans and blood tests to see how well the medications are working. This is a single-center study, meaning you would receive your treatment at one research hospital location.
AI-generated summary from trial data · Jun 15, 2026 · Not medical advice
China
Phase
Safety & dosing / Early efficacy
Sponsor
Jun Guo
Enrollment target
~50 participants
Started
August 2023
Primary completion
December 2026
Age range
18 Years and older
Last updated on clinicaltrials.gov in March 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Jun Guo
Peking University Cancer Hospital & Institute
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.